EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models

Kaori Abe iD, Tadashi Watabe iD, Kazuko Kaneda-Nakashima iD, Yoshifumi Shirakami iD, Yuichiro Kadonaga, Sadahiro Naka, Kazuhiro Ooe iD, Atsushi Toyoshima, Frederik Giesel, Takeshi Usui iD, Nanae Masunaga iD, Chieko Mishima und 7 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252111567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kaori Abe und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Japanese Science and Technology Agency (JST) and KAKENHI Grant-in-Aid for Scientific Research, Japanese Science and Technology Agency (JST), KAKENHI Grant-in-Aid for Scientific Research (C).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) presents limited therapeutic options and is associated with poor prognosis. Early detection and the development of novel therapeutic agents are therefore imperative. Fibroblast activation protein (FAP) is a membrane protein expressed on cancer-associated fibroblasts (CAFs) that plays an essential role in TNBC proliferation, migration, and invasion. Consequently, it is hypothesized that the Astatine (211At)-labeled FAP inhibitor (FAPI) selectively exerts anti-tumor effects through alpha-particle emission. In this study, we aimed to assess its theranostic capabilities by integrating [18F]FAPI-74 PET imaging with targeted alpha therapy using [211At]FAPI1 in TNBC models. Mice xenografts were established by transplanting MDA-MB-231 and HT1080 cells (control). As a parallel diagnostic method, [18F]FAPI-74 was administered for PET imaging to validate FAP expression. A single dose of [211At]FAPI1 (1.04 ± 0.10 MBq) was administered to evaluate the therapeutic efficacy. [18F]FAPI-74 exhibited high accumulation in MDA-MB-231 xenografts, and FAP expression was pathologically confirmed via immunostaining. The group that received [211At]FAPI1 (n = 11) demonstrated a significantly enhanced anti-tumor effect compared with the control group (n = 7) (p = 0.002). In conclusion, [18F]FAPI-74 PET imaging was successfully used to diagnose FAP expression, and as [211At]FAPI1 showed promising therapeutic efficacy in TNBC models, it is expected to be a viable therapeutic option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsXenograft Model Antitumor AssaysAnimalsHumansMiceFemaleCell Line, TumorPositron-Emission TomographyAstatineAlpha ParticlesMembrane ProteinsEndopeptidasesSerine EndopeptidasesMice, NudeGelatinasesRadiopharmaceuticalsMice, Inbred BALB CFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

Astatine (211At)CAFFAPFAPI-PET[211At]FAPI1theranosticstriple-negative breast cancerα-emitting nuclides

Substanzen

AstatineMembrane ProteinsEndopeptidasesSerine EndopeptidasesGelatinasesRadiopharmaceuticalsFibroblast Activation Protein Alpha

Autor:innen und Institutionen

  • Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.
  • Department of Radiology, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.
  • Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan.
  • Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Medicine, Osaka University, Suita 560-0043, Japan.
  • Department of Pharmacy, Osaka University Hospital, Suita 565-0871, Japan.
  • Department of Nuclear Medicine, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University, 40225 Duesseldorf, Germany.

ORCID-Profile: Kaori Abe, Tadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Kazuhiro Ooe, Takeshi Usui, Nanae Masunaga, Masami Tsukabe, Yoshiaki Sota

Förderung

  • the Japanese Science and Technology Agency (JST) and KAKENHI Grant-in-Aid for Scientific Research
  • Japanese Science and Technology Agency (JST)
  • KAKENHI Grant-in-Aid for Scientific Research (C)

Zitieren

APA

Abe, K., Watabe, T., Kaneda-Nakashima, K., Shirakami, Y., Kadonaga, Y., Naka, S., Ooe, K., Toyoshima, A., Giesel, F., Usui, T., Masunaga, N., Mishima, C., Tsukabe, M., Yoshinami, T., Sota, Y., Miyake, T., Tanei, T., Shimoda, M., & Shimazu, K. (2024). Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111567

Vancouver

Abe K, Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Naka S, et al. Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111567

BibTeX
@article{Abe2024,
  author = {Abe, Kaori and Watabe, Tadashi and Kaneda-Nakashima, Kazuko and Shirakami, Yoshifumi and Kadonaga, Yuichiro and Naka, Sadahiro and Ooe, Kazuhiro and Toyoshima, Atsushi and Giesel, Frederik and Usui, Takeshi and Masunaga, Nanae and Mishima, Chieko and Tsukabe, Masami and Yoshinami, Tetsuhiro and Sota, Yoshiaki and Miyake, Tomohiro and Tanei, Tomonori and Shimoda, Masafumi and Shimazu, Kenzo},
  title = {Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252111567}
}
Kostenlos starten →